SGHT Share Price Performance
US$9.05
5.44 (150.69%)
81.0% overvalued intrinsic discount
US$5.00
Fair Value
Price US$9.05
AnalystHighTarget US$5.00
AnalystLowTarget US$3.60
AnalystConsensusTarget US$7.85
Fair ValueUS$5.00
Share Pricen/a
Sight Sciences, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
SGHT Community Narratives
AN
Fair Value US$5 81.0% overvalued intrinsic discount
Aging Demographics And Emerging Markets Will Expand Eye Care Access
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$3.6 151.4% overvalued intrinsic discount
Restrictive Reimbursement Will Undermine Ophthalmic Margins While Slow Recovery Emerges
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$7.85 15.3% overvalued intrinsic discount
Expanding Healthcare Access And Chronic Eye Disease Trends Will Boost Minimally Invasive Procedures
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Expanding Healthcare Access And Chronic Eye Disease Trends Will Boost Minimally Invasive Procedures
Key Takeaways Expanding chronic eye disease prevalence and innovation in minimally invasive solutions are driving strong demand, higher utilization, and opportunities for accelerated growth and margin expansion. A large unreached market for dry eye therapy and anticipated regulatory milestones position the company for significant future growth in revenue and market share.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$7.85
15.3% overvalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
12.96% p.a.
Profit Margin
12.91%
Future PE
39.7x
Price in 2028
US$9.72
Aging Demographics And Emerging Markets Will Expand Eye Care Access
Key Takeaways Rapid product innovation and strong clinical adoption could drive significant revenue growth, gross margin expansion, and near-monopoly positioning in minimally invasive eye care. International expansion, potential litigation windfalls, and demographic trends create multiple underappreciated opportunities for diversified growth and enhanced long-term profitability.Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$5
81.0% overvalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
20.6% p.a.
Profit Margin
12.32%
Future PE
21.69x
Price in 2028
US$6.22
Restrictive Reimbursement Will Undermine Ophthalmic Margins While Slow Recovery Emerges
Key Takeaways Narrow product focus and vulnerability to reimbursement restrictions threaten Sight Sciences' revenue growth and long-term margin stability. Persistent unprofitability, high expenses, and technological disruption risks may drive continued shareholder dilution and declining market relevance.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$3.6
151.4% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
4.1% p.a.
Profit Margin
12.42%
Future PE
24.95x
Price in 2028
US$4.52
Trending Discussion
Recently Updated Narratives
AN
SGHT: Final Medicare Coverage Will Shape Dry Eye Outlook And Execution Risks
Fair Value: US$7.85 15.3% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Restrictive Reimbursement Will Undermine Ophthalmic Margins While Slow Recovery Emerges
Fair Value: US$3.6 151.4% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Demographics And Emerging Markets Will Expand Eye Care Access
Fair Value: US$5 81.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sight Sciences, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.87
- 86.05%
- -60.63%
- 62.3%
About SGHT
- Founded
- 2010
- Employees
- 216
- CEO
- WebsiteView website
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
